Arbutus Biopharma vs Valneva
Valneva is the larger business, with $197m of revenue in fiscal 2025 against $14.1m for Arbutus Biopharma (14.0 times as much). Arbutus Biopharma grew faster (128.2% against 7.6%). Valneva kept more of each dollar of sales as profit: a net margin of -66.0% against -237.9%. Arbutus Biopharma carries less debt relative to equity (0.0% against 168.8%).
| Latest fiscal year | Arbutus BiopharmaABUS, 2025 | ValnevaVALN, 2025 |
|---|---|---|
| Revenue | $14.1m | $197m |
| Revenue growth | 128.2% | 7.6% |
| Net income | −$33.5m | −$130m |
| Operating margin | -271.0% | -47.0% |
| Net margin | -237.9% | -66.0% |
| Return on equity | -38.5% | -83.4% |
| Free cash flow | −$39.6m | −$64.8m |
| Cash | $18.0m | $129m |
| Total debt | $0 | $210m |
| Debt to equity | 0.0% | 168.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | — |
| Market value | $791m | $461m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |